Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Killing the Last 0.1%: Targeting Cancer Persister Cells June 15, 2026
- Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer June 15, 2026
- Newsletter 24/2026 June 14, 2026
- Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026
Phase 1 Recruiting: IMP1734 (EIK1003), A New PARP1 Inhibitor for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Recruiting: GSK5764227 Targets B7-H3 in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxGrape Seed Extract Shows Potential to Slow Prostate Cancer Progression
/in Clinical Trial, Non-Metastatic, Phase 2/by MaxOvercoming Resistance in Metastatic Prostate Cancer: Repurposing Pimitespib
/in Drug repurposing, Preclinical Research/by MaxBA1106 Antibody Shows Promise in Early Trials In Solid Tumors
/in Clinical Trial, Not PCa related/by MaxQ702 Drug Shows Promise in Early Trials: Could Be Useful Against Prostate Cancer
/in Clinical Trial, Not PCa related/by MaxNezastomig (REGN5678): New Drug Combo Shows Promise In mCRPC, But Safety Is A Concern
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA New Potential Treatment For Early Prostate Cancer: TGW101
/in Clinical Trial, Non-Metastatic, Not PCa related, Phase 1/by Max